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Original Communication
Clinical Relevancy
Patients with chronic intestinal failure may develop intestinal 
failure–associated liver disease (IFALD) as a result of several 
factors relating to chronic intestinal failure, including but not 
limited to parenteral nutrition administration.
Liver biopsy is the reference standard to diagnose IFALD, but 
the associated complications preclude its use on a regular basis. 
Steatosis is a dominant feature of IFALD in adults. This study 
shows that proton magnetic resonance spectroscopy is a reliable 
method to quantify liver fat content in patients with chronic intes-
tinal failure who are receiving long-term parenteral nutrition, if 
correction is implemented for possible accumulation of paramag-
netic home parenteral nutrition trace elements in the liver. Proton 
magnetic resonance spectroscopy can be used in future trials to 
assess treatment effects of IFALD-related steatosis.
Introduction
Intestinal failure–associated liver disease (IFALD)—that is, 
liver damage due to intestinal failure or its treatment by means 
of parenteral nutrition (PN)—covers the complete spectrum, 
from elevated liver enzymes to end-stage liver disease. 
Depending on the definition used, 20%–75% of adult patients 
receiving home PN (HPN) develop IFALD,1 and death due to 
IFALD is reported in about 3% of the adult patient population 
with chronic intestinal failure.2 The etiology of IFALD is most 
likely multifactorial.3-5
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Abstract
Background: Intestinal failure–associated liver disease is a frequent complication in patients with chronic intestinal failure (CIF), with 
steatosis as a dominant feature in adults. Proton magnetic resonance spectroscopy (1H-MRS) is a noninvasive method to quantify liver fat 
content (LFC). In this study, LFC was assessed with 1H-MRS, taking into account the possible accumulation of paramagnetic components 
of home parenteral nutrition (HPN) that may disturb these measurements. Methods: LFC was measured in 15 adult CIF patients who had 
been receiving HPN for >6 months. 1H-MR spectra were obtained with a 3 Tesla magnetic resonance (MR) system, with a method correcting 
for the presence of paramagnetic ions. Patients with low (<5%) versus high (≥5%, steatosis) LFC were compared with nonparametric 
statistical tests. Results: 1H-MRS analysis revealed steatosis in 5 patients (median, 10.3%), while 10 patients had normal LFC (median, 
0.9%). In all patients, the 1H-MRS results indicated the presence of various amounts of paramagnetic constituents in the liver. Patients 
with steatosis had higher alanine aminotransferase values than patients without steatosis (median, 60 vs 28 U/L). Unexpectedly, in the 
steatosis group, the frequency of HPN use was lower, with significant lower total HPN and carbohydrate calories. In 1 patient, MR 
spectra were of inferior quality, with broadened resonances after infusion with a ferric compound. Conclusion: 1H-MRS enables reliable 
noninvasive assessment of LFC in patients receiving long-term HPN, if correcting for possible accumulation of paramagnetic components 
in the liver. However, LFC determination by 1H-MRS is not recommended after a recent ferric compound infusion. (JPEN J Parenter 
Enteral Nutr. XXXX;xx:xx-xx)
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Although liver biopsy remains the reference to diagnose 
IFALD, many centers will not perform liver biopsies on a regu-
lar basis, because of the invasive nature of the procedure. 
Therefore, elevations of liver enzymes are generally used as 
surrogate markers, but these seem to be of little help to monitor 
for the onset and progression of IFALD.6 The predominant his-
tologic finding in adults with IFALD is hepatic steatosis.7,8 
IFALD progression in adults is typically insidious and is often 
recognized only when liver injury has become irreversible.9
Owing partly to the traditional invasive liver fat measure-
ment, the evidence is scarce for the progression and/or the effects 
of interventions on steatosis in patients receiving HPN.8,10,11
Proton magnetic resonance spectroscopy (1H-MRS) is a 
noninvasive method to quantify liver fat content (LFC) by ana-
lyzing the intensities of water and fat signals in a magnetic 
resonance (MR) spectrum from the liver. Because values 
obtained by 1H-MRS correlate well with liver biopsy results, it 
is considered an optimal noninvasive method to quantify 
hepatic steatosis.12-14 Furthermore, 1H-MRS is a suitable tech-
nique to monitor metabolic changes due to disease and to fol-
low treatment.15,16
As with MR imaging, 1H-MRS uses magnetic properties of 
protons to create signals. However, 1H-MRS does not produce 
images but spectra in which the signals originating from pro-
tons in water and fat appear at different frequencies (Figure 1). 
1H-MRS signal intensities are affected by the relaxation behav-
ior of the corresponding proton spins in the magnetic field. 
Water and lipid signals both decrease as an exponential function 
of the echo time (TE) of the 1H-MRS pulse sequence, with a 
faster decline of the water signal than that of the lipid signal 
(Figure 1). Often, a relatively short TE is used to minimize 
these effects in LFC determination by 1H-MRS. However, 
patients receiving HPN usually receive commercial multi–trace 
element admixtures, with the risk for oversupplementation and 
accumulation of paramagnetic constituents, such as iron, cop-
per and manganese in the liver,17 in addition to physiologically 
variable liver iron. In the presence of these paramagnetic com-
ponents, the fall in water signal intensity is even steeper, caused 
by shortened T2 relaxation (Figure 1). This effect may result in 
an overestimation of lipid:water ratio and falsely increased 
LFC. However, when MR spectra with multiple TEs are 
acquired, the correct signal intensities of lipid and water can be 
obtained by an extrapolation of both signal intensities to their 
values at a TE of 0 milliseconds. In this way the increased rela-
tive effect due to the presence of paramagnetic components is 
eliminated, and a correct LFC can be determined.18
Liver complications are a particular concern in patients 
receiving long-term PN therapy. Noninvasive monitoring with 
early detection and implementation of a treatment plan aiming 
to avoid hepatic damage is essential to maintain high-quality 
HPN support. This notion urged us to assess LFC with 1H-MRS 
in patients receiving long-term HPN, taking into account the 
possibility of altered relative MR signal intensities of water 
and lipid by components of the PN additives.
Materials and Methods
Patients
Fifteen outpatients who were under the care of the Intestinal 
Failure Unit of the Department of Gastroenterology and 
Hepatology of the Radboud University Medical Center, 
Nijmegen, The Netherlands, were invited for this study during 
a regular checkup. All were >18 years and had been receiving 
HPN for >6 months because of chronic intestinal failure due to 
a benign underlying condition. Patients with extrahepatic 
causes of liver test abnormalities and those with known viral 
hepatotoxicity were excluded. HPN formulations were indi-
vidualized with respect to electrolytes and caloric intake, but 
all patients received overnight cyclic infusions of PN formula-
tion enriched with water- and fat-soluble vitamins (Cernevit; 
Baxter, Maurepas, France) and trace elements (Addamel; 
Fresenius Kabi, Emmer-Compascuum, Netherlands) over 10–
12 hours, with a caloric intake close to 25–30 kcal/kg per HPN 
day. Most patients had residual oral intake. The study was 
approved by the local Medical Ethics Committee. All subjects 
gave written informed consent.
Magnetic Resonance Investigations
MR studies of the liver were performed on a clinical 3 Tesla MR 
system (Tim Trio Whole Body Magnetic Resonance Scanner; 
Siemens, Erlangen, Germany) with the body coil for excitation 
and 2 phased-array surface coils positioned at the liver and the 
abdomen for signal reception, with the patient in a supine posi-
tion. Imaging of the liver was performed with the standard 
Figure 1. Multiple-echo magnetic resonance spectra of the liver. 
In the presence of paramagnetic ions, the water signal decays 
faster with increasing echo time (TE), while the (smaller) decay 
of the lipid signal is hardly affected.
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clinical unenhanced MR liver-imaging protocol. This protocol 
included acquisition of localizers in 3 orthogonal directions dur-
ing breath holding, axial T1-weighted spoiled gradient echo in-
phase and opposed phase imaging (for water and fat signal) 
during multiple breath holds, T2-weighted coronal and axial 
HASTE (half-Fourier acquisition single-shot turbo spin echo) 
imaging during multiple breath holds, axial T2-weighted 
respiratory-triggered turbo spin echo imaging with and without 
fat saturation, and axial diffusion-weighted imaging with EPI 
(echo planar imaging) during a breath hold.
LFC was assessed by 1H-MRS on the same system using 
the images obtained for voxel placement. Single-voxel 1H-MR 
spectra were acquired from a volume of 30 × 30 × 30 mm3 
positioned in the center of the right liver lobe, avoiding large 
vessel structures (Figure 2). A STEAM localization sequence 
without water suppression was used for data acquisition. To 
allow for correction of relaxation effects on signal intensity, 
both long repetition time (3 seconds) and 4 TEs (20, 30, 40, 
and 50 milliseconds) were used. Six averages were obtained 
during breath holding for 18 seconds. For each TE, the 1H-MRS 
measurement was performed in duplicate. Measurements were 
performed at least 6 hours after the last PN infusion. 
Postprocessing was performed in exactly the same way for all 
patients and consisted of time-domain fitting of the water sig-
nal resonating at 4.7 ppm and the methylene lipid peak at 
1.3 ppm with the AMARES quantification method in the 
jMRUI analysis software (www.jmrui.eu). For reliable deter-
mination of the LFC, shortened T2 relaxation behavior of 
water18—possibly due to hepatic accumulation of paramag-
netic PN constituents such as iron, manganese, and copper—
has to be taken into account. To correct for T2 relaxation, the 
ratio of the signal intensities of lipid (L) and water (W) was 
plotted as a function of TE. L/W was determined for each TE 
separately to eliminate effects of possible amplitude variation 
among subsequently acquired spectra. It is not possible to 
directly measure the L/W at TE = 0 milliseconds, or (L/W)0, 
which is the time point where T2 relaxation effects are absent. 
Therefore, an exponential function L/W = (L/W)0·exp(TE*K) 
with K = (1/T2W – 1/T2L) was fitted to the data to obtain the 
value (L/W)0, with GraphPad Prism (version 5.03; GraphPad 
Software, Inc, La Jolla, CA), with goodness of fit expressed as 
an R2 value. LFC in percentage, defined as 100 × [L/(W + L)] 
at TE = 0 milliseconds, was calculated by the formula [100 × 
(L/W)0] / [1 + (L/W)0].
A reference K value of 0.015 milliseconds-1 was calculated 
from literature values for T2 of water and lipid (T2W and T2L) of 
34 and 68 milliseconds, respectively, at a magnetic field of 3 T.19,20
Data Handling and Statistical Analysis
For all patients, the following data were recorded: sex, age, 
body mass index (kg/m2), cause of intestinal failure, clinical 
classification of intestinal failure according to the guideline of 
the European Society for Clinical Nutrition and Metabolism,6 
duration of HPN use and frequency of HPN days per week, 
amount of energy, and amount of carbohydrates and lipids per 
kg body weight infused by HPN at the time of 1H-MRS mea-
surement. Furthermore, liver enzymes were collected: alkaline 
phosphatase, γ-glutamyl transferase, aspartate aminotransfer-
ase, alanine aminotransferase, total bilirubin, and direct biliru-
bin. If available, serum levels of iron, iron-binding capacity, 
ferritin, C-reactive protein, manganese, and copper were 
recorded from the patient’s medical chart. Information on the 
presence of diabetes, known alcohol abuse (defined as >1 unit 
per day), and concomitant medication was collected as well. 
Patient demographics and clinical characteristics were pre-
sented as medians (interquartile ranges) or actual patient num-
bers (percentages). Patients with normal (<5%) versus increased 
(≥5%) LFC14 were compared with the Mann-Whitney U test for 
continuous variables and Fisher’s exact test for binary variables 
(SPSS 22; IBM, Chicago, Illinois). A 2-sided P < .05 was con-
sidered statistically significant.
Results
1H-MRS analysis revealed increased LFC (≥5%) in 5 patients 
(Figure 3), with a median value of 10.3% (Table 1), while 10 
patients had normal LFC (0.9%).
Liver 1H-MR spectra of good quality were obtained in 14 
of 15 patients. Figure 4 shows an example of the liver MR 
spectra of a patient with normal LFC and one with high LFC. 
A higher signal is present at a resonance frequency of 1.3 ppm 
for the patient with increased LFC, which represents the lipid 
signal.
Figure 5 shows for 2 patients the L/W as a function of TE 
with an exponential fit. These 2 patients have similar LFC 
(approximately 2%), which can be calculated from the inter-
cept of the curve—(L/W)0 at TE = 0 milliseconds—but they 
have different relaxation behavior, with K values of 0.035 and 
0.016 milliseconds-1 (ie, different time constants of the expo-
nential curves). Figure 5 illustrates that if LFC would be calcu-
lated from the L/W at TE ≥20 milliseconds, LFC would be 
Figure 2. Voxel position (box) in a liver on an axial slice.
4 Journal of Parenteral and Enteral Nutrition XX(X)
overestimated. This is especially valid for patient 1, who has a 
higher K value than patient 2, as visualized by a faster expo-
nential increase of L/W as a function of TE. This suggests a 
higher accumulation of paramagnetic components in the liver 
of patient 1 than in the liver of patient 2.
The mean R2 value of the goodness of fit of the exponential 
function for 14 of 15 patients was 0.97, with a standard devia-
tion of 0.03. For 1 patient, who received an iron dextran com-
plex within 2 weeks before the examination, 1H-MRS spectra 
were not representative. Spectra of this patient showed broad-
ened resonances, and the signal-to-noise ratio was reduced, 
especially at the longest TEs (40 and 50 milliseconds). The R2 
value of the goodness of fit of the exponential function was 
considerably lower for this patient, being 0.65. All patients 
showed shortened T2 relaxation behavior of water to some 
extent, which can be extracted from an increased K value. K 
values obtained in our study population were in the range 
between 0.016 and 0.035 milliseconds-1, which is higher than 
the reference value of 0.015 milliseconds-1.
Table 1 and Supplementary Tables S1 and S2 provide 
patients’ demographical and clinical characteristics. When the 
characteristics between the patients with normal (<5%) and 
increased (≥5%) LFC were compared, patients with increased 
LFC had a higher median alanine aminotransferase value (60 
vs 28 U/L). Unexpectedly, among patients with increased LFC, 
the frequency of HPN days per week was lower than in the 
group with normal LFC, 4 and 7 days, respectively. 
Furthermore, the median of calories (per kg body weight per 
week) provided by HPN was higher in the group with normal 
LFC (180.5 vs 151.1 kcal), as was the amount of infused 
carbohydrates (1540 vs 900 g). All other characteristics were 
comparable between the 2 groups.
In all patients, serum iron levels and iron-binding capacity 
were determined, and the values were within or below the refer-
ence range (data not shown). In 5 patients, ferritin was measured 
as well, with an elevated concentration in 3 of them, with slightly 
elevated C-reactive protein in 2 patients. In the third patient, fer-
ritin concentration was very high (3632 µg/L) following a recent 
(within 2 weeks prior to 1H-MRS measurement) infusion of a 
ferric compound because of anemia. Plasma manganese (refer-
ence value, 7–20 nmol/L) was assessed in only 3 patients close 
to the date of the 1H-MRS measurement. One of these patients 
had a significantly increased manganese plasma level of 49.3 
nmol/L combined with cholestatic liver enzymes; therefore, 
supplementation of lipids, lipid-soluble vitamins, and trace ele-
ments was terminated. No recent serum copper levels were 
available for any of the patients. MR imaging revealed addi-
tional findings in 10 patients: cholelithiasis in 6 patients, 
enlarged adrenal gland in 2, (hepato)splenomegaly in 1, and cho-
ledochocystolithiasis with normal liver tests in 1 patient.
Discussion
In our current study, LFC was assessed in 15 adult patients 
receiving long-term HPN with noninvasive 1H-MRS, taking 
into account the possibility of accumulation of paramagnetic 
constituents in the liver. Representative 1H-MRS spectra were 
obtained in 14 of 15 patients, and we found elevated LFC in 5 
patients. To accurately quantify liver fat, 1H-MRS must reflect 
water and fat content without influences from other factors, 
because liver lipid calculation relies on the ratio between lipid 
and water amounts. Therefore, the 1H-MRS spectra in our study 
were acquired with a long repetition time and multiple TEs to 
allow correction of the signal amplitudes for water and fat for 
(altered) relaxation effects.18 This is of particular importance in 
the determination of LFC, as it has been shown that paramag-
netic components in the liver unequally affect the MR signals of 
water and lipid.21 This may be the result of these components 
localizing preferentially in the water compartment, causing 
greater susceptibility effects on water protons. The consequence 
is a disproportionately faster loss in liver water signal relative to 
lipid signal, and this decay may falsely augment measured LFC 
with traditional, uncorrected 1H-MRS sequences. Our patients 
who use long-term HPN with addition of paramagnetic trace ele-
ments such as manganese, copper, and iron from fixed-concen-
tration trace element supplements are probably even more prone 
to this effect than the general population due to possible liver 
accumulation of these trace elements.6,17,22,23 This is supported 
by the fact that all patients showed increased K values compared 
with the reference value of 0.015 milliseconds-1, indicating 
shortened T2 relaxation behavior of water probably due to accu-
mulation of paramagnetic constituents in the liver. A limitation 
of our study is that we have no histology to prove this assump-
tion. As an alternative, we looked at available serum iron levels, 
iron-binding capacity, and ferritin levels, as well as serum 
Figure 3. Scatter plot of liver fat content of 15 patients with 
chronic intestinal failure who were receiving long-term home 
parenteral nutrition, determined by proton magnetic resonance 
spectroscopy. Horizontal line in the graph is the upper level of 
normal for liver fat content (5%).
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manganese and copper levels. In 1 patient with a high ferritin 
concentration (3632 µg/L) after recent transfusion with a ferric 
compound, very broadened resonances of the 1H-MRS spectra 
were seen, probably due to high amounts of iron accumulation in 
the liver. Except for the results obtained in this 1 patient, our 
results are in line with those of Kang and colleagues, who 
showed that the assessment of hepatic steatosis with 1H-MRS 
with multiecho acquisition to correct for T2 effects was not 
affected by hepatic iron deposition.24 The results of Kang et al 
may not be applicable to patients with exceptionally high iron 
deposition, as these patients were not included in that study.
Regular monitoring of patients receiving fixed doses of 
manganese over prolonged periods is recommended,6 but there 
is no readily available indicator of whole body manganese sta-
tus. Elevated serum, plasma, red blood cell, and whole blood 
manganese concentrations have been reported in patients 
receiving PN, usually without symptoms, also at conventional 
doses between 0.15 and 0.8 mg/d when taken over a prolonged 
period.6,25 It is very well possible that, without reaching levels 
of toxicity, manganese that has accumulated in the liver influ-
ences 1H-MRS signals, especially because manganese is 
mainly excreted in the bile and because hepatic dysfunction 
and cholestasis are suspected risk factors for increased manga-
nese accumulation. The same can be said for copper, as this 
trace element is also mainly excreted in bile.6,26
Hepatic steatosis is an important histologic feature in adult 
patients with IFALD.8 A small proportion of patients with 
chronic intestinal failure are at risk of developing serious liver 
complications, including end-stage liver disease. Early inter-
ventions may prevent these adverse outcomes. The accuracy 
and safety of 1H-MRS make it a good methodology to assess 
LFC, to examine changes in steatosis over time, or to deter-
mine changes in response to therapeutic interventions. One 
study previously reported on the clinical application of 
1H-MRS in 6 adult patients receiving long-term HPN.11 The 
results were compared with 6 healthy controls, and a signifi-
cant difference in lipid:water ratio was found. In this study, 
1H-MRS spectra were measured at a single TE (35 millisec-
onds); thus, no correction was made for the confounding T2 
relaxation effects. Furthermore, LFC was defined differently 
than in our study, and it is therefore difficult to compare their 
result with ours.
Table 1. Patient Demographics and Clinical Characteristics.a
Liver Fat Content
Characteristic Normal, <5% (n = 10) Increased ≥5% (n = 5) P Value
Liver fat content 0.9 [0.7–1.8] 10.3 [9.1–19.3] .001
Female 7 (70) 3 (60) 1.00
Age, y 52.1 [33.7–61.0] 47.7 [38.6–59.2] .68
Body mass index, kg/m2 21.5 [18.8–23.0] 21.5 [20.1–26.4] .51
Liver enzymes  
 Bilirubin, µmol/L  
  Total 10.5 [7.3–21.3] 10.0 [7.5–20.5] .77
  Direct <5 [<5–9.5] <5 [<5–12.5] .86
 Other, U/L  
  ALP 137 [115–301] 245 [128–360] .31
  yGT 60 [40–258] 95 [57–436] .90
  AST 32 [26–42] 51 [33–78] .11
  ALT 28 [22–42] 60 [40–120] .03
Duration HPN,b mo 42.5 [23.8–79.8] 46.0 [25.5–236.5] .44
Frequency, d/wk  
 HPN 7 [5–7] 4 [2.5–5.5] .02
 Lipid infusion 5 [2–6.3] 4 [1.5–5.5] .59
Total kcal via HPNc 209.2 [171.8–229.2] 151.1 [66.1–168.0] .01
Amount of infusion, gc  
 Carbohydrate 1540 [1310–2450] 900 [660–1135] .003
 Lipid 5.5 [2.0–6.9] 5.5 [1.9–6.9] 1.00
Diabetes mellitus 1 (10) 0 (0) 1.00
Known alcohol abuse 1 (10) 0 (0) .33
Steatosis inducing concomitant medication 2 (20) 0 (0) .52
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HPN home parenteral nutrition; yGT, γ-glutamyl 
transferase.
aValues are presented as median [interquartile range] or No. (%) of affected patients. P values are based on Mann-Whitney U test or Fisher’s exact test.
bDuration of HPN at time of proton magnetic resonance spectroscopy measurement (in months).
cPer kg body weight per week.
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Ideally, our findings should be confirmed comparing 1H-MRS 
with liver biopsies in this population, but because of its invasive 
nature, there are ethical concerns to perform the biopsy for 
research purposes. However, 1H-MRS has increasingly been 
accepted as an alternative to liver biopsy to assess and quantify 
hepatic steatosis and is now regarded as one of the most adequate 
practical methods of measuring liver fat in clinical practice,13 
especially for longitudinal follow-up of patients. Furthermore, 
with MR imaging, which can be performed in 1 session, it pro-
vides information on hepatic and bile duct anatomy.
A limitation of using 1H-MRS is that no information is 
obtained on liver inflammation or fibrosis. Currently, there is no 
information on the outcomes for patients with and without 
IFALD-related steatosis. But the use of 1H-MRS could provide 
more insight into this, because noninvasive follow-up is possi-
ble. Another potential drawback is that 1H-MRS cannot be per-
formed in all patients (eg, in those with metal-containing 
devices or claustrophobia), and the technique is currently not 
readily available in all hospitals. Conventional ultrasound can 
be used to show moderate to severe steatosis at low cost, is eas-
ily accessible, and can be used as a point-of-care test during a 
clinic visit. However, conventional ultrasound is typically not 
recommended when an accurate diagnosis or precise severity 
grading is required. Quantitative ultrasound technique might be 
a good alternative in the future. Computer-aided ultrasound—a 
technique that was recently evaluated within our group to quan-
tify hepatic steatosis—showed a good correlation between the 
residual attenuation coefficient (one of the parameters obtained 
by computer-aided ultrasound) and LFC measured by 1H-MRS 
Figure 4. Liver magnetic resonance spectra (echo time = 20 milliseconds) of 2 patients with low (A) and high (B) LFC. Water indicates 
water signal; lipid indicates lipid methylene signal (resonance frequency at 4.7 and 1.3 ppm, respectively).
Figure 5. Correction for T2 relaxation effects. Lipid/water 
as function of echo time with an exponential fit of 2 patients. 
Similar liver fat content but different relaxation behavior. Liver 
fat content can be calculated with the lipid:water ratio at an echo 
time of 0 milliseconds.
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in our pilot group of long-term patients receiving HPN.27 
Additional research will need to be done to bolster these data.
The results of the present pilot study, although limited in sam-
ple size, shows higher alanine aminotransferase values in the ste-
atosis group than in the patient group with normal LFC. The other 
liver enzymes were comparable between the 2 groups. As the use 
of PN is considered to be an important risk factor for developing 
IFALD,3,9,28 PN characteristics were compared between the 
groups with high and normal LFC. Surprisingly, the patients with 
normal LFC had more HPN infusion days per week, with more 
HPN calories per week, than the steatosis group. The high LFC 
could furthermore not be explained by differences in type of lipid 
emulsion, the duration, or the amount of lipids infused (Table 1, 
Supplementary Table S2). Other risk factors for steatosis—such 
as body mass index, alcohol use, diabetes, or concomitant use of 
steatosis-inducing medication, were comparable between the 2 
groups (Table 1). Other factors possibly play a role, such as oral 
food intake of energy, physical activity, or other implicated risk 
factors of IFALD not evaluated in this study.9
In conclusion, our results show that 1H-MRS is suitable to 
quantify LFC in adult patients receiving long-term HPN, as 
long as altered T2 relaxation behavior is taken into account. 
LFC measured by 1H-MRS seems less reliable after recent fer-
ric compound infusion, which should be kept in mind in plan-
ning 1H-MRS in this patient group. Factors explaining the 
difference in LFC were not identified.
Supplementary Material
Supplementary Tables S1 and S2 are available with the online 
article at http://journals.sagepub.com/home/pen.
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